Bayer and Ginkgo launch microbe company – Chemical & Engineering News
Chemical & Engineering News |
Bayer and Ginkgo launch microbe company
Chemical & Engineering News Bayer and Ginkgo Bioworks are forming a new company to exploit the potential of synthetic biology to improve microbes that help plants grow. The unnamed firm launches with a $100 million investment from the parent companies and Viking Global Investors. |
OncLive |
Study Finds Hyperprogression After Immunotherapy in NSCLC Subset
OncLive Although anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer (NSCLC) and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor … |
Futurism |
Geneticists Have Used CRISPR Gene Editing to Create Crops That Grow More Food
Futurism Researchers from Cold Spring Harbor Laboratory in New York have developed a method of editing crops to increase yield using CRISPR-Cas9. The difference between their technique and others is that they didn’t target the “yield” genes themselves. Plant geneticists develop a new application of CRISPR to break yield barriers in cropsPhys.Org |
News at Louisiana Tech |
2017-18 ‘New Frontiers’ series opens Oct. 2 with ‘immunotherapy‘ presentation
News at Louisiana Tech “His presentation on immunotherapy and its relation to oncology will both inspire and challenge our current students and faculty.” “The opportunities for our faculty, students, and community to interact with world-class researchers and biomedical … |
The Voice Online |
This student’s lifesaving mission for blood stem cell donors
The Voice Online IN 2006, Zainab Garba-Sani’s friend received a life-changing blood stem cell donation to treat her sickle cell anaemia. Inspired to overcome the lack of awareness around blood cancers and disorders, Zainab’s now on a mission with the blood cancer … |
Healthcare Packaging |
Good News: FDA Approves Gene Therapy for Cancer. Bad News: It Costs $475k
Healthcare Packaging A recent article from MIT Technology Review discussed the FDA’s approval of a groundbreaking gene therapy for cancer that uses genetically engineered immune cells. The process, developed by Novartis, is known as a CAR-T therapy and it will cost … |